PMID- 8230263
OWN - NLM
STAT- MEDLINE
DCOM- 19931201
LR  - 20220223
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 85
IP  - 22
DP  - 1993 Nov 17
TI  - Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal 
      fluid and cyst fluid from patients with malignant glioma.
PG  - 1836-9
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein 
      that attracts monocytes. In vitro studies have reported high levels of MCP-1 
      messenger RNA expression, as well as the presence of MCP-1, in malignant glioma 
      cells. PURPOSE: Our purpose was to determine whether an MCP-1 assay could be used 
      in a clinical setting 1) to differentiate malignant from benign gliomas and from 
      nontumor disorders of the central nervous system and 2) to detect subarachnoid 
      dissemination of glioma cells. METHODS: MCP-1 levels in cerebrospinal fluid (CSF) 
      and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay 
      (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples 
      from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, 
      six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients 
      with benign glioma, and seven patients with nontumor disorders of the central 
      nervous system. Cyst fluids from four patients with malignant glioma (anaplastic 
      astrocytoma) were also tested. The correlation between MCP-1 concentration in the 
      CSF and subarachnoid dissemination of malignant glioma cells was also studied. 
      RESULTS: The MCP-1 concentration (mean +/- SE) in CSF samples from patients with 
      malignant glioma (2.3 +/- 0.4 ng/mL) was significantly higher than that from 
      patients with benign glioma (0.6 +/- 0.1 ng/mL) (P < .01) or from patients with 
      no tumor (0.5 +/- 0.1 ng/mL) (P < .01). Furthermore, CSF samples from patients 
      with subarachnoid dissemination of malignant glioma contained significantly 
      higher amounts of MCP-1 than those from patients without dissemination (P < .05). 
      Cyst fluids from four of the patients with malignant glioma contained high 
      concentrations of MCP-1. CONCLUSIONS: These results indicate that MCP-1 is 
      produced by malignant glioma in vivo as well as in vitro and suggest that testing 
      for MCP-1 in CSF may be useful in the clinic to differentiate malignant glioma 
      from benign glioma and to detect subarachnoid dissemination of the tumor cells. 
      IMPLICATIONS: The MCP-1 ELISA in CSF may lead to more accurate diagnosis of 
      malignant glioma and detection of subarachnoid dissemination of tumor cells, 
      facilitating selection of patients with these conditions for appropriate therapy.
FAU - Kuratsu, J
AU  - Kuratsu J
AD  - Department of Neurosurgery, Kumamoto University Medical School, Japan.
FAU - Yoshizato, K
AU  - Yoshizato K
FAU - Yoshimura, T
AU  - Yoshimura T
FAU - Leonard, E J
AU  - Leonard EJ
FAU - Takeshima, H
AU  - Takeshima H
FAU - Ushio, Y
AU  - Ushio Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemotactic Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Body Fluids/metabolism
MH  - Brain Neoplasms/cerebrospinal fluid/*metabolism
MH  - Central Nervous System Diseases/metabolism
MH  - Chemokine CCL2
MH  - Chemotactic Factors/cerebrospinal fluid/*metabolism
MH  - Child
MH  - Child, Preschool
MH  - Cysts/metabolism
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Female
MH  - Glioma/cerebrospinal fluid/*metabolism/secondary
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/secondary
MH  - Middle Aged
MH  - Subarachnoid Space
EDAT- 1993/11/17 00:00
MHDA- 1993/11/17 00:01
CRDT- 1993/11/17 00:00
PHST- 1993/11/17 00:00 [pubmed]
PHST- 1993/11/17 00:01 [medline]
PHST- 1993/11/17 00:00 [entrez]
AID - 10.1093/jnci/85.22.1836 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9. doi: 10.1093/jnci/85.22.1836.